A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004

J Bone Miner Res. 2005 Dec;20(12):2275-82. doi: 10.1359/jbmr.2005.20.12.2274.
No abstract available

Publication types

  • Biography
  • Classical Article
  • Historical Article
  • Portrait

MeSH terms

  • Antibodies, Monoclonal / history
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Carrier Proteins / immunology
  • Denosumab
  • Female
  • History, 21st Century
  • Humans
  • Membrane Glycoproteins / immunology
  • Osteoporosis, Postmenopausal / drug therapy*
  • Osteoporosis, Postmenopausal / history
  • RANK Ligand
  • Randomized Controlled Trials as Topic
  • Receptor Activator of Nuclear Factor-kappa B

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Carrier Proteins
  • Membrane Glycoproteins
  • RANK Ligand
  • Receptor Activator of Nuclear Factor-kappa B
  • TNFRSF11A protein, human
  • TNFSF11 protein, human
  • Denosumab

Personal name as subject

  • Pirow J Bekker
  • Donna L Holloway
  • Amy S Rasmussen
  • Robyn Murphy
  • Steven W Martin
  • Philip T Leese
  • Gregory B Holmes
  • Colin R Dunstan
  • Alex M DePaoli